Research programme: metabolic disorder therapeutics - Caldan Therapeutics
Latest Information Update: 28 Oct 2023
At a glance
- Originator University of Glasgow; University of Southern Denmark
- Developer Caldan Therapeutics
- Class Antihyperglycaemics; Hepatoprotectants; Small molecules
- Mechanism of Action GPR120 protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Non-alcoholic steatohepatitis; Type 2 diabetes mellitus
Most Recent Events
- 28 Oct 2023 No recent reports of development identified for research development in Type-2-diabetes-mellitus in United Kingdom (PO)
- 28 Sep 2023 No recent reports of development identified for research development in Non-alcoholic-steatohepatitis in United Kingdom
- 04 Sep 2019 Early research in Type 2 diabetes mellitus in United Kingdom (PO)